Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [2810]

ASH 2022: Chemotherapy-free regimen ponatinib plus blinatumomab effective in patients with newly diagnosed Ph+ ALL

ASH 2022: Chemotherapy-free regimen ponatinib plus blinatumomab effective in patients with newly diagnosed Ph+ ALL

ASH 2022: Older or high-risk patients with newly diagnosed AML respond well to triplet therapy

ASH 2022: Older or high-risk patients with newly diagnosed AML respond well to triplet therapy

ASH 2022: New data for talquetamab, a first-in-class GPRC5DxCD3 bispecific antibody, suggesting durable responses in patients with heavily pretreated multiple myeloma

ASH 2022: New data for talquetamab, a first-in-class GPRC5DxCD3 bispecific antibody, suggesting durable responses...

ASH 2022: Novel drug shows early promise in treating multiple myeloma

ASH 2022: Novel drug shows early promise in treating multiple myeloma

ASH 2022: Efficacy and subgroup analyses from MAIA study showing long-term results of daratumumab based regimen in newly diagnosed, transplant-ineligible MM

ASH 2022: Efficacy and subgroup analyses from MAIA study showing long-term results of daratumumab based regimen in...

ASH 2022: Researchers present new approach to understanding challenging CAR T-cell toxicities

ASH 2022: Researchers present new approach to understanding challenging CAR T-cell toxicities

ASH 2022: Talquetamab generates high response rate in patients with hard-to-treat multiple myeloma

ASH 2022: Talquetamab generates high response rate in patients with hard-to-treat multiple myeloma

ASH 2022: Extending chemotherapy slashes risk of aggressive childhood leukaemia coming back

ASH 2022: Extending chemotherapy slashes risk of aggressive childhood leukaemia coming back

$FDA approves olutasidenib for relapsed or refractory acute myeloid leukaemia with a susceptible IDH1 mutation$

FDA approves olutasidenib for relapsed or refractory acute myeloid leukaemia with a susceptible IDH1 mutation

How AI found the words to kill cancer cells

How AI found the words to kill cancer cells

More from ecancer